This genomics stock appears to be at an inflection point.Guardant Health (GH +0.68%) is on the rise, in more ways than one. Shares of the precision oncology company have skyrocketed over the last six months. Guardant Health has also chalked up several key victories recently, including signing a multi-year collaboration with Merck (MRK +1.35%) to develop companion diagnostics and market new cancer therapies with Guardant's Infinity Smart program. Although Guardant Health hasn't announced a date for releasing ...

still underperforming the broader market. However, the chart master says that energy may be reaching an inflection point and it could be higher from here. Carter Worth looking at the charts on energy now.>> Sure. Let's get right to it. So, I've got five identical charts.The first, as is always the case, has nothing on it. Now, let's put some things on it. The next uh shows uh converging trend lines.Uh we reached a point where something is likely to happen. My judgment is up. Uh but let's take it back a litt ...